BioNTech SE (Nasdaq: BNTX) has announced it will present new clinical data from its lung cancer development programme at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea, running from 12–15 September 2026. The disclosures will span key assets pumitamig and gotistobart, alongside mRNA-based immunotherapy candidates. Notably, a late-breaking oral presentation will deliver the first clinical data for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate in lung cancer, marking a significant milestone in BioNTech's novel-novel combination strategy.

Key Points

  • BioNTech SE ADR (0A3M / Nasdaq: BNTX), a global next-generation biopharmaceutical company headquartered in Mainz, Germany
  • BioNTech will present clinical data at WCLC 2026 in Seoul, including the first pumitamig plus elfetabart drozuntecan combination results in lung cancer
  • Updated overall survival data from the PRESERVE-003 Phase 3 trial of gotistobart in squamous NSCLC will also be presented; BioNTech has 16 ongoing lung cancer trials including five Phase 3 studies
  • Investors should watch for the oral presentation on 15 September 2026 and updated Phase 3 survival readouts that could inform BioNTech's regulatory pathway

First Clinical Data for Pumitamig Combined with B7H3-Targeting ADC Elfetabart Drozuntecan in NSCLC and SCLC

The headline data presentation at WCLC 2026 will cover the global Phase 1/2 trial (NCT06892548) evaluating pumitamig — a PD-L1xVEGF-A bispecific immunomodulator developed with Bristol Myers Squibb — in combination with elfetabart drozuntecan (BNT324/DB-1311), a B7H3-targeted antibody-drug conjugate developed with Duality Biologics. The announcement states this represents the first combination data for any PD-(L)1xVEGF bispecific immunomodulator and an ADC across any lung cancer setting, covering patients with both advanced or metastatic non-small cell lung cancer and small cell lung cancer. This oral presentation is scheduled for 15 September 2026.

PRESERVE-003 Phase 3 Gotistobart Overall Survival Update in Squamous NSCLC After Prior Immunotherapy

BioNTech will also present updated overall survival data from stage 1 of the PRESERVE-003 Phase 3 clinical trial (NCT05671510), evaluating gotistobart — a tumour microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4, developed with OncoC4 — in patients with squamous NSCLC who progressed following prior PD-(L)1 inhibitor treatment. The announcement describes this as a chemotherapy-free approach in the second- and later-line setting. The pivotal stage 2 portion of PRESERVE-003 remains ongoing, meaning further data readouts are anticipated before any regulatory submission could be considered.

BioNTech's Broader Lung Cancer Pipeline Spans 16 Trials Across Multiple Subtypes and Biomarkers

Beyond the headline presentations, BioNTech's WCLC 2026 programme includes data from pumitamig in unresectable malignant mesothelioma, two Phase 3 trials-in-progress posters for the ROSETTA Lung-201 and ROSETTA Lung-202 studies comparing pumitamig against durvalumab and pembrolizumab respectively, and preliminary Phase 1 results for mRNA-based immunotherapy candidate BNT116 combined with cemiplimab in resectable NSCLC. The announcement states BioNTech currently has 16 ongoing lung cancer clinical trials in total, spanning five pivotal Phase 3 studies and two novel-novel combination trials across subtypes, biomarkers, and treatment settings.